COPYRIGHT© 2018 吉林紫鑫药业股份有限公司
Announcement on Resolutions of the Sixth Meeting of the Fifth Board of Directors of Jilin Zixin Pharmaceutical Co., Ltd.
Stock code: 002118 Securities abbreviation: Zixin Pharmaceutical Announcement No.: 2013-037
Jilin Zixin Pharmaceutical Co., Ltd.
Announcement on Resolutions of the Sixth Meeting of the Fifth Board of Directors
Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as "the company") The sixth meeting of the fifth board of directors was held on October 9, 2013 by way of on-site voting. The meeting was notified by phone, email on September 27, 2013. Issuance in other ways, in accordance with the provisions of the "Company Law" and "Articles of Association". The meeting should attend 7 directors and actually attend 7 directors. The convening of this meeting is in line with the relevant provisions of the Company Law and the Articles of Association. The convening procedures and voting results of this meeting are legal and valid.
The meeting was held in the conference room of the company. After careful consideration by the directors at the meeting, the following proposals were passed:
I. The “Proposal on Applying for Working Capital Loans to Changchun Ruixiang Sub-branch of Jilin Bank Co., Ltd.” was considered and approved.
The result of the review: 7 votes in favor, 0 votes against, and 0 abstentions.
1. Apply to the Changchun Ruixiang Sub-branch of Jilin Bank Co., Ltd. for a working capital loan of no more than RMB 100 million to supplement the working capital. The loan period is one year.
2. The guarantee method of the above loan is stock pledge, and the company's controlling shareholder Dunhua Kangping Investment Co., Ltd. holds the unrestricted shares of the company as pledge.
3. Authorized financial manager Shao Tianyu has full authority to handle the loan procedures.
2. The “Proposal on Temporary Supplementary Liquidity for the Use of Investment Funds” was reviewed and approved.
Review results: 7 votes in favor, 0 votes against, 0 abstentions
The company plans to use the 40 million yuan idle raised funds to temporarily supplement the working capital, accounting for 4.05% of the net proceeds, and the use period is no more than 5 months, from October 10, 2013 to March 9, 2014.
Independent directors of the company issued independent opinions.
Jilin Zixin Pharmaceutical Co., Ltd. Board of Directors
October 11, 2013